Présentation de l'entreprise
Scinai Immunotherapeutics Ltd., trading under the ticker SCNI, is a biopharmaceutical enterprise dedicated to the development, manufacturing, and commercialization of biological products specifically designed to treat inflammation and immunology conditions. The company's core focus lies in creating nanosized VHH antibodies, also known as nanoAbs, which target infectious and autoimmune diseases, primarily within the Israeli market. Operating within the healthcare sector and the biotechnology industry, the firm positions itself as a specialized developer of innovative therapeutic modalities rather than a broad-based manufacturer. With a market capitalization of $2.05M and annual revenue of $1.31M, the company operates on a micro-cap scale, indicating it is in a nascent or early-stage phase of commercialization where revenue generation is still limited relative to market size. The absence of reported employee data suggests the organization likely maintains a lean operational structure typical of early-stage biotech firms relying heavily on intellectual property and external partnerships rather than large-scale internal production facilities.
Santé financière
The company reported revenue of $1.31M over the trailing twelve months, accompanied by a net income loss of $-8,307,000 and an EBITDA of $-6,121,000. The significant disparity between the $1.31M revenue and the $-8,307,000 net income reveals a cost structure characterized by substantial operating expenses, likely driven by research and development costs inherent to the biotechnology industry. Free cash flow stands at $-3,408,750, indicating that current cash generation is insufficient to cover operational expenditures, which limits immediate financial flexibility without additional capital infusion. Analysis of the three primary margins shows a gross margin of -202.3%, an operating margin of -702.4%, and a profit margin of 0.0%, all of which reflect the intense burn rate typical of companies in the development phase where costs exceed revenue significantly. The balance sheet presents a leveraged position with total debt of $2.27M against cash holdings of $1.66M, resulting in a debt-to-equity ratio of 27.98. This ratio indicates that the company is heavily reliant on equity financing rather than debt, yet the negative cash flow exacerbates the risk associated with the existing debt obligations. Liquidity is assessed via a current ratio of 1.30, which suggests the company possesses sufficient current assets to cover short-term liabilities, though the margin is tight given the negative operating environment. Return on equity is recorded at -91.9% and return on assets at -37.6%, metrics that demonstrate management's current inability to generate positive returns on shareholder capital or the asset base, a common characteristic for pre-commercialization biotech entities.
Évaluation de la valorisation
Valuation metrics for Scinai Immunotherapeutics Ltd. are constrained by its lack of profitability, resulting in a trailing P/E ratio of N/A and a forward P/E of N/A. The absence of these traditional earnings-based multiples implies that investors cannot value the stock based on current or expected earnings per share, necessitating the use of alternative valuation frameworks. The price-to-book ratio is 0.39, indicating that the market values the company at less than one-third of its net asset book value, suggesting a discount relative to the underlying assets recorded on the balance sheet. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 1.56 and an EV/EBITDA of -1315.56, figures that highlight the speculative nature of the valuation and the heavy negative enterprise value relative to earnings. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $6.18 and a 52-week low of $0.55. Without a specific current price provided in the data, the position relative to this range cannot be precisely calculated, but the wide spread between the high and low underscores the high risk and potential for significant price swings typical of small-cap biotechnology stocks. A beta value of N/A is reported, meaning volatility relative to the broader market is not quantifiable through standard regression analysis, further complicating risk assessment for portfolio diversification purposes.
Growth & Income
Revenue growth year-over-year is recorded at 30.6%, while earnings growth is listed as N/A due to the company's continued losses. The absence of earnings growth data confirms that profitability has not yet been achieved, implying that the company is prioritizing revenue expansion and product development over immediate profit generation. As a non-dividend payer, Scinai Immunotherapeutics Ltd. reports a dividend yield of N/A and a payout ratio of 0.0%, reflecting a strategy of reinvesting all available resources into research, development, and operational scaling rather than distributing income to shareholders. This reinvestment approach is standard for biotechnology firms in the development stage but carries the risk of dilution if equity financing is required to sustain the negative free cash flow. The overall growth and income profile is defined by rapid revenue expansion coupled with significant financial distress and no current shareholder distributions, positioning the asset as a high-risk, high-potential growth vehicle dependent on future commercial success.